OCTOBER 2009
AAA Migration Resistance
Dr. Vito Mantese, Vascular Surgeon, St. Louis Vascular Center
The Zenith Flex
endograft has many exceptional features. One of the most important is its ability to resist migration because of its proximal fixation mechanism. The transrenal stents, combined with barbs, are a proven combination for migration prevention. This Zenith Flex endograft also resists migration because it is placed so that the graft bifurcation is near the native aortic bifurcation. In addition, the graft is versatile so that common iliac artery coverage can be maximized. All of these features help prevent graft migration and subsequent endoleak.Another highly valuable feature of the Zenith Flex graft is its delivery system, which allows for high precision placement and the user's ability to easily readjust the graft position prior to deployment of the transrenal barbs. By deploying the graft sequentially, the system allows the user to maintain control throughout the entire process.
Industry Update
An Interview with Dr. Frank J. Veith
As the VEITHsymposium in New York City, NY, approaches, we at the Landing Zone thought it would be interesting to learn more about the meeting and the man behind it. Dr. Frank Veith was gracious enough to take time out of his busy schedule to sit down and chat with us. Below are some of the highlights of the conversation:- Since taking over the meeting, Dr. Veith has seen it grow from a small regional meeting with a faculty of 20 to the premier educational meeting with a faculty of almost 400 medical professionals.
- Over the years, the symposium format has changed from long presentations on few topics to a more rapid-fire approach featuring presentations no longer than 5 minutes that cover a wide range of topics.
- Dr. Veith was a pioneer in linking with industry, stemming from his belief that it is the relationship between medical device companies and physicians that sparks the greatest innovation. This is why there is such a large industry presence at the meeting.
Management Message
ARC Technology(tm) - The Zenith Advantage
Phil Nowell, Global Leader, Aortic Intervention, Cook MedicalZenith AAA endografts entered the U.S. market in 2003 and were immediately adopted as the graft of choice for many physicians because of their precision delivery and ability to stay where placed. Initial studies showed virtually no migration and extremely low rates of endoleaks or secondary interventions. In 2008, the five-year clinical data demonstrated that Zenith could maintain its early performance, as the graft continued to show rates of migration, endoleaks and secondary intervention near zero.
So what does Zenith have that makes this possible while other grafts on the market continue to "struggle" to remain fixed in place and maintain a good seal?
Product Spotlight
Revolutionary Drug-eluting Stent Launched in Europe
New Zilver
PTX Drug-Eluting Stent
In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its-kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union.Created by Cook Medical, the new CE Marked Zilver PTX Drug-Eluting Peripheral Stent is widely expected to improve the standard of care for many patients with serious blockages in the superficial femoral artery (SFA) by creating a highly effective, completely new treatment option.
Upcoming EVAR Events
-
Vascular Interventional Advances (VIVA)
October 19-23
Las Vegas, Nevada -
Association of Thoracic and Cardiovascular Surgeons of Asia (ATCSA)
October 25-28
Seoul, South Korea -
The Australasian Society of Cardiac and Thoracic Surgeons (ASCTS)
November 5-8
Noosa, Queensland, Australia -
Vascular Society AGM
November 18-20
Liverpool, England -
VEITHsymposium
November 18-22
New York, NY
About Zenith
Cook Medical proudly produces the Zenith family of EVAR products. Included are the Zenith Flex AAA Endovascular Graft, a model for precision in the treatment of abdominal aneurysms, and the TX2 TAA Endovascular Graft, which offers unparalleled control in the treatment of thoracic aneurysms.The Landing Zone is a monthly publication from Cook Medical for EVAR Specialists. To read the complete articles, please visit landingzone.cookmedical.com
COOK MEDICAL INCORPORATED
P.O. Box 4195,
Bloomington, IN
47402-4195 U.S.A.
Phone: 812.339.2235,
Toll Free: 800.457.4500
Toll Free Fax: 800.554.8335
COOK (CANADA) INC.
111 Sandiford Drive,
Stouffville, Ontario,
L4A 7X5 CANADA
Phone: 905.640.7110
Toll Free: 800.668.0300
COOK AUSTRALIA
95 Brandl Street
Eight Mile Plains
Brisbane, QLD 4113 AUSTRALIA
Phone: +61 7 38 41 11 88
WILLIAM COOK EUROPE ApS
Sandet 6, DK-4632,
Bjaeverskov, DENMARK
Phone: +45 56 86 86 86
